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O ver the past decade, optimism has beenhigh for the potential clinical signiﬁcanceof glycogen synthase kinase–3 (GSK-3) as a
pharmacological target for ischemia and heart failure,
as well as diabetes, Parkinson’s disease, and Alz-
heimer’s disease. GSK-3 is expressed as 2 isoforms,
a and b, which are encoded by separate genes. Human
data suggest that GSK-3 is inhibited in the failing
heart (1–3). Exciting proteomic discoveries have iden-
tiﬁed that activated GSK-3b targets and phosphory-
lates z-disc proteins as well as myosin-binding
protein C, stabilizing force kinetics and calcium sensi-
tivity (2–4). In the failing human heart, GSK-3b is
inhibited, leading to decreased phosphorylation of
speciﬁc z-disc proteins, reduced force kinetics, and
diminished calcium sensitivity (2). Cardiac resynchro-
nization therapy activates GSK-3b, improving
contractility in association with phosphorylation of
multiple z-disc targets (2). Taken together, these ﬁnd-
ings suggest that GSK-3b activation may be a beneﬁ-
cial molecular mechanism to improve functional
kinetics in the chronic failing heart.
In response to a myocardial infarction, an imme-
diate goal is to restrict scar expansion and preserve
function. Landmark data from Tong et al. (5) in 2002
showed that beneﬁcial ischemic preconditioning was
associated with GSK-3 phosphorylation and inhibition
in rats. Strong evidence now supports a role for GSK-3
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National Institutes of Health.transition pore in the mechanism of protection of
ischemic preconditioning (6).In this issue of the Journal, Ahmad et al. (7) report
the results of a study testing whether the deletion of
GSK-3a in the heart would alter the response to
chronic ischemia (a permanent occlusion of the left
anterior descending coronary artery). To do this,
they established a genetic mouse model in which
GSK-3a was deleted conditionally and speciﬁcally in
the heart. One might expect that deleting GSK-3a
would replicate the protective effects of GSK-3
inhibition under conditions of ischemia. Indeed,
deletion of GSK-3a in the heart just before ischemia
preserved cardiac function, limited cardiovascular
remodeling, and restricted scar expansion over the
course of 8 weeks (Fig. 1). The mechanistic data
supporting these conclusions included a decrease in
cardiac myocyte apoptosis and an increase in pro-
liferation. The decrease in apoptosis (ranging from
0.0% to 0.4%) was associated with an increase in the
antiapoptotic gene Bcl-2 and a decrease in the pro-
apoptotic gene Bax. The investigators show addi-
tional data supporting a role for E2F-1 and cyclin E1
recruitment in association with increased cardiac
myocyte proliferation (7). Infarct size at 48 h was
unchanged in mice with and without GSK-3a. At
8 weeks, cellular markers of hypertrophy and heart
weight were also unchanged, along with ﬁbrosis
biomarkers in the remote regions. Interestingly, the
inducible GSK-3b cardiac-speciﬁc knockout mice
showed similar ﬁndings after left anterior descend-
ing coronary artery occlusion: less left ventricular
dilation and improved function, as well as increased
cardiac myocyte proliferation (8).
Could inhibition of GSK-3a or GSK-3b in cardiac
myocytes be used clinically to restrict scar expansion
and preserve function in patients after myocardial
FIGURE 1 Deletion of GSK-3a in Cardiac Myocytes
(A) Chronic ischemia in the presence of glycogen synthase kinase (GSK)-3a. (B) Chronic ischemia in the absence of GSK-3a. Reduced cardiac
function, cardiovascular remodeling, and scar tissue often accompany chronic ischemia. If GSK–3a is deleted just before chronic ischemia in the
cardiac myocytes using an inducible cardiac myocyte–speciﬁc GSK-3a-knockout mouse model, scar formation is restricted, cardiovascular
function is preserved, and remodeling is reduced.
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708infarction? Next steps would include testing this
hypothesis in a large animal model.
The roles of GSK-3a and GSK-3b in response to
different stresses have been controversial. In science,
medicine, and discovery, we feel a sense of security
when mechanism(s) as to why a particular therapy
works or fails are understood. Security or reassurance
increases with different approaches arriving at the
same answer. For example, reassurance is enhanced
through the elucidation of mechanisms using gain-of-
function and loss-of-function approaches, the
inclusion of different pre-clinical models, and human
data. Scientists are driven to question the data and
design the most rigorous experiments to test the
hypothesis. In the case of GSK-3a, the established and
characterized mouse models include global knock-
outs, tissue-speciﬁc inducible knockouts, and trans-
genic overexpressing models. For example, in this
issue of the Journal, an inducible cardiac myocyte
speciﬁc GSK-3a-knockout mouse model preservedcardiac function and restricted expansion of the scar
in the setting of chronic ischemia in association with
decreased myocyte apoptosis (7). Data from the
cardiac myocyte–speciﬁc overexpressing GSK-3amice
exhibiting increased myocyte apoptosis with smaller
hearts at baseline add reassurance to a working
model that decreasing GSK-3a in the myocyte de-
creases myocyte apoptosis (7) and increasing GSK-3a
expression in the myocyte increases myocyte
apoptosis (9).
Inducible cardiac myocyte–speciﬁc deletion of
GSK-3b results in better preservation of cardiovas-
cular function after chronic ischemia and increased
proliferation, similar to the phenotype in this issue of
the Journal from an inducible cardiac myocyte–
speciﬁc deletion of GSK-3a in response to chronic
ischemia (7,8). Thus, inducible cardiac myocyte
deletion of GSK-3a or GSK-3b is protective after
ischemia. However, data from the whole-body GSK-
3a-knockout model subjected to chronic ischemia
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709exhibited opposite results: cardiac rupture and death
in association with increased myocyte apoptosis
during the ﬁrst 10 days (10). The data from this whole-
body GSK-3a-knockout model are challenging to
ﬁgure out and cast an intriguing question with regard
to the potential molecular roles of GSK-3a in multiple
cell types, throughout development, adulthood, and
in response to stressors.
In conclusion, the work of Ahmad et al. (7) is an
important step forward in ascertaining a speciﬁc role
of GSK-3a in the cardiac myocyte under conditions of
chronic stress. This issue of the Journal provides newpre-clinical data suggesting that deletion of GSK-3a
just before chronic ischemia is beneﬁcial (7).
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